JP4425141B2 - 非小細胞肺癌の診断のための方法 - Google Patents

非小細胞肺癌の診断のための方法 Download PDF

Info

Publication number
JP4425141B2
JP4425141B2 JP2004541231A JP2004541231A JP4425141B2 JP 4425141 B2 JP4425141 B2 JP 4425141B2 JP 2004541231 A JP2004541231 A JP 2004541231A JP 2004541231 A JP2004541231 A JP 2004541231A JP 4425141 B2 JP4425141 B2 JP 4425141B2
Authority
JP
Japan
Prior art keywords
nsc
gene
expression
protein
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004541231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006500949A5 (enExample
JP2006500949A (ja
Inventor
祐輔 中村
弥太郎 醍醐
修一 中鶴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2006500949A publication Critical patent/JP2006500949A/ja
Publication of JP2006500949A5 publication Critical patent/JP2006500949A5/ja
Application granted granted Critical
Publication of JP4425141B2 publication Critical patent/JP4425141B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
JP2004541231A 2002-09-30 2003-09-22 非小細胞肺癌の診断のための方法 Expired - Fee Related JP4425141B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41467302P 2002-09-30 2002-09-30
US45137403P 2003-02-28 2003-02-28
US46610003P 2003-04-28 2003-04-28
PCT/JP2003/012072 WO2004031413A2 (en) 2002-09-30 2003-09-22 Method for diagnosing non-small cell lung cancers

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009138122A Division JP4921522B2 (ja) 2002-09-30 2009-06-09 非小細胞肺癌の診断のための方法
JP2009231138A Division JP2010042016A (ja) 2002-09-30 2009-10-05 非小細胞肺癌の診断のための方法

Publications (3)

Publication Number Publication Date
JP2006500949A JP2006500949A (ja) 2006-01-12
JP2006500949A5 JP2006500949A5 (enExample) 2006-11-02
JP4425141B2 true JP4425141B2 (ja) 2010-03-03

Family

ID=32074369

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004541231A Expired - Fee Related JP4425141B2 (ja) 2002-09-30 2003-09-22 非小細胞肺癌の診断のための方法
JP2009138122A Expired - Fee Related JP4921522B2 (ja) 2002-09-30 2009-06-09 非小細胞肺癌の診断のための方法
JP2009231138A Pending JP2010042016A (ja) 2002-09-30 2009-10-05 非小細胞肺癌の診断のための方法
JP2012003039A Pending JP2012125247A (ja) 2002-09-30 2012-01-11 非小細胞肺癌の診断のための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009138122A Expired - Fee Related JP4921522B2 (ja) 2002-09-30 2009-06-09 非小細胞肺癌の診断のための方法
JP2009231138A Pending JP2010042016A (ja) 2002-09-30 2009-10-05 非小細胞肺癌の診断のための方法
JP2012003039A Pending JP2012125247A (ja) 2002-09-30 2012-01-11 非小細胞肺癌の診断のための方法

Country Status (8)

Country Link
EP (30) EP2270210A3 (enExample)
JP (4) JP4425141B2 (enExample)
KR (2) KR20110020953A (enExample)
AT (1) ATE541053T1 (enExample)
AU (1) AU2003272088A1 (enExample)
CA (1) CA2500151A1 (enExample)
TW (1) TW200413725A (enExample)
WO (1) WO2004031413A2 (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300469A (en) * 1992-12-08 1994-04-05 Engelhard Corporation Composition for passivating vanadium in catalytic cracking and preparation thereof
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
EP1576131A4 (en) * 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
CA2512337A1 (en) * 2003-01-03 2004-07-29 Gencia Corporation Sirna mediated post-transcriptional gene silencing of genes involved in alopecia
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1730533A1 (en) * 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
TW200533376A (en) * 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
ATE483979T1 (de) * 2004-08-10 2010-10-15 Oncotherapy Science Inc Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa
EP1786925B1 (en) * 2004-08-10 2010-12-08 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
EP1799854B1 (en) * 2004-09-24 2010-09-01 Oncotherapy Science, Inc. METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8
ATE451619T1 (de) * 2004-10-19 2009-12-15 Onco Therapy Science Inc Pkp3-onkogen als prognostischer indikator für lungenadenokarzinom
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
BRPI0519096A2 (pt) * 2004-12-15 2008-12-23 Beth Israel Hospital Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
PL2325306T3 (pl) 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1
EP1854473A1 (en) * 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
EP1888639A1 (en) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
CN101273144B (zh) * 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
KR100759288B1 (ko) * 2005-11-14 2007-09-17 가톨릭대학교 산학협력단 비교유전자보합법을 이용한 폐암 및 폐암의 하부유형 진단방법
CN101415440A (zh) 2006-02-10 2009-04-22 肿瘤疗法科学股份有限公司 治疗肺癌的方法
JP2009536516A (ja) * 2006-04-20 2009-10-15 オンコセラピー・サイエンス株式会社 肺癌の治療標的としてのＮＭＵ−ＧＨＳＲ１ｂ／ＮＴＳＲ１発癌シグナル伝達経路
WO2008014951A1 (en) * 2006-08-01 2008-02-07 Roche Diagnostics Gmbh Use of nnmt as a marker for lung cancer
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
WO2008020652A1 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
WO2008020653A1 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Use of holliday junction-recognizing protein related to cancer
US20100292090A1 (en) 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2008026946A2 (en) * 2006-08-30 2008-03-06 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
EP2687540A1 (en) 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
WO2008072777A2 (en) 2006-12-13 2008-06-19 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer
KR100846354B1 (ko) * 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
EP2142648A4 (en) * 2007-03-30 2011-09-14 Oncotherapy Science Inc SCREENING AND THERAPEUTIC PROCEDURE FOR NSCLC WITH THE CDCA8-AURKB COMPLEX AS A GOAL
WO2008151110A2 (en) * 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
JP2010535014A (ja) * 2007-07-30 2010-11-18 オンコセラピー・サイエンス株式会社 癌関連遺伝子ｌｙ６ｋ
US8455444B2 (en) 2007-08-20 2013-06-04 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
MX2010002002A (es) 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido foxm1 y agente medicinal que lo contiene.
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
CA2705509A1 (en) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-gpr49 antibody
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2010001585A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
EP2334789A1 (en) * 2008-08-27 2011-06-22 Oncotherapy Science, Inc. Breast cancer related gene rqcd1
WO2010023856A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Pancreatic cancer related gene ttll4
RU2011111411A (ru) * 2008-08-28 2012-10-10 Онкотерапи Сайенс, Инк. (Jp) Oip5 в качестве гена-мишени для терапии и диагностики рака
KR101064561B1 (ko) * 2008-09-24 2011-09-14 고려대학교 산학협력단 폐선암 수술 후 초기 재발 예측용 바이오마커
US20110301056A1 (en) * 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
CA3024643C (en) 2009-03-12 2021-08-03 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
HUE037593T2 (hu) 2009-09-03 2018-09-28 Toray Industries Immunitásindukáló
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
JP5838482B2 (ja) 2010-03-11 2016-01-06 オンコセラピー・サイエンス株式会社 Ｈｊｕｒｐペプチドおよびそれを含むワクチン
WO2011129427A1 (ja) * 2010-04-16 2011-10-20 第一三共株式会社 癌の診断剤および治療剤
WO2012016082A1 (en) 2010-07-30 2012-02-02 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
US8933050B2 (en) 2010-09-02 2015-01-13 Institute National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment and the diagnosis of cancer
CA2834383A1 (en) * 2011-04-29 2012-11-01 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2012153492A1 (en) * 2011-05-06 2012-11-15 Oncotherapy Science, Inc. Nptx2 as tumor marker and therapeutic target for cancer
WO2012157239A1 (en) * 2011-05-16 2012-11-22 Oncotherapy Science, Inc. Chodl as tumor marker and therapeutic target for cancer
KR102015648B1 (ko) 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신
US9926604B2 (en) 2011-10-14 2018-03-27 The Regents Of The University Of California Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
CN104968345B (zh) 2012-01-19 2018-05-08 肿瘤疗法科学股份有限公司 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂
KR101308924B1 (ko) * 2012-02-21 2013-09-23 차의과학대학교 산학협력단 신규한 ｍｉＲＮＡ ｈｃ－ｓｍＲ－Ｓ２－５ 및 이의 용도
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US9687538B2 (en) 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
US9644010B2 (en) 2012-07-10 2017-05-09 Oncotherapy Science, Inc. LY6K epitope peptides for TH1 cells and vaccines containing the same
GB201213229D0 (en) * 2012-07-25 2012-09-05 Isis Innovation Assay
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR101447901B1 (ko) 2013-04-16 2014-10-16 한양대학교 산학협력단 지방세포 표적 비바이러스성 유전자 전달체
TWI643867B (zh) 2013-05-24 2018-12-11 日商腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗
CN107208131A (zh) 2014-05-30 2017-09-26 基因中心治疗公司 用于肺癌分型的方法
EP4353321A3 (en) 2014-08-04 2024-07-10 OncoTherapy Science, Inc. Koc1-derived peptide and vaccine including same
RU2700881C2 (ru) 2014-08-04 2019-09-23 Онкотерапи Сайенс, Инк. Пептид, полученный из urlc10, и содержащая его вакцина
JPWO2016121715A1 (ja) * 2015-01-26 2017-11-02 国立大学法人名古屋大学 肺がん患者の予後を評価するための情報を提供する方法、肺がん患者の予後予測方法、内部標準、抗体、肺がん患者の予後予測装置、予後予測装置のプログラム及び記録媒体
CA2982775A1 (en) * 2015-04-14 2016-10-20 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
US20190185851A1 (en) * 2015-09-09 2019-06-20 Theoria Science Inc. Exosome secretion inhibitor
JP6873482B2 (ja) 2015-10-08 2021-05-19 オンコセラピー・サイエンス株式会社 Ｆｏｘｍ１由来ペプチドおよびそれを含むワクチン
HK1251928A1 (en) 2015-10-08 2019-05-03 Oncotherapy Science, Inc. MPHOSPH1-derived peptides and vaccines including it
EP3458612B1 (en) 2016-05-17 2023-11-15 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
CN109863251B (zh) 2016-05-17 2022-11-18 基因中心治疗公司 对肺鳞状细胞癌亚型分型的方法
IL264826B2 (en) 2016-08-31 2024-06-01 Oncotherapy Science Inc Monoclonal antibody against melk and utilization thereof
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
NL2020004B1 (en) 2016-12-09 2018-07-02 Ary Flohil Jacob Treatment of diffuse intrinsic pontine glioma
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
EP3607089A4 (en) 2017-04-04 2020-12-30 Lung Cancer Proteomics, LLC PLASMA-BASED PROTEIN PROFILING FOR EARLY PROGNOSIS OF LUNG CANCER
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
EP4006983B1 (en) 2019-07-31 2026-04-22 BOE Technology Group Co., Ltd. Display substrate and preparation method therefor, display panel, and display apparatus
KR102540416B1 (ko) * 2021-04-09 2023-06-12 주식회사 애티스랩 암 진단용 조성물, 키트, 및 이를 이용한 암 진단 방법
KR102732170B1 (ko) 2021-05-20 2024-11-19 한국식품연구원 구강미생물 정보를 이용한 폐암의 조기진단 및 위험성 예측 방법 또는 이를 위한 조성물
CN113925877B (zh) * 2021-10-28 2022-06-07 青岛西凯生物技术有限公司 基因增强型免疫细胞在肺癌中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9114005D0 (en) 1991-06-28 1991-08-14 Automotive Prod Plc A clutch control system
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5403494A (en) 1993-07-15 1995-04-04 The Lawrence Paper Company Method of recovery of single color printing ink wastes
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1053319A2 (en) * 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
WO1999058675A2 (en) * 1998-05-14 1999-11-18 Chiron Corporation Human genes and gene expression products v
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
EP1396543A3 (en) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
DE60045201D1 (de) * 1999-08-12 2010-12-16 Agensys Inc C-Typ-Lektin-Transmembran-Antigen, das in menschlichem Prostatakrebs exprimiert wird, und Verwendungen dieses Antigens
CA2399776A1 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001072781A2 (en) * 2000-03-28 2001-10-04 Chiron Corporation Human genes and expression products
US20020119156A1 (en) 2000-03-29 2002-08-29 Sei-Yu Chen Compositions and methods of diagnosing, monitoring, staging, imaging and treating lung cancer
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1358349A2 (en) * 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
EP1343886A2 (en) * 2000-07-11 2003-09-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20070015148A1 (en) * 2001-01-25 2007-01-18 Orr Michael S Gene expression profiles in breast tissue
EP1377596B1 (en) * 2001-02-21 2012-04-11 Novartis Vaccines and Diagnostics, Inc. Ttk in diagnosis and as a therapeutic target in cancer
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
TW200533376A (en) * 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
PL2325306T3 (pl) * 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1
US20100292090A1 (en) * 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2009028580A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis

Also Published As

Publication number Publication date
EP2270225A3 (en) 2011-10-05
EP2264185A1 (en) 2010-12-22
EP2270210A3 (en) 2011-06-22
EP2270215A2 (en) 2011-01-05
EP2270502A3 (en) 2011-01-26
ATE541053T1 (de) 2012-01-15
EP2270501A2 (en) 2011-01-05
EP2270217A2 (en) 2011-01-05
EP1743947B1 (en) 2012-01-11
EP1551998A2 (en) 2005-07-13
EP2270222A2 (en) 2011-01-05
EP2270212A3 (en) 2011-06-29
EP2270499A1 (en) 2011-01-05
KR20110020953A (ko) 2011-03-03
EP1743947A3 (en) 2007-05-23
EP2270221A3 (en) 2011-09-28
EP2270218A2 (en) 2011-01-05
EP2270211A2 (en) 2011-01-05
JP2010042016A (ja) 2010-02-25
TW200413725A (en) 2004-08-01
EP2270215A3 (en) 2011-07-20
EP2270216A2 (en) 2011-01-05
EP2270224A3 (en) 2011-10-05
EP2270225A2 (en) 2011-01-05
AU2003272088A1 (en) 2004-04-23
EP2270217A3 (en) 2011-07-27
EP2270503A3 (en) 2011-01-19
EP2270502A2 (en) 2011-01-05
EP2270221A2 (en) 2011-01-05
AU2003272088A8 (en) 2004-04-23
EP2270498A3 (en) 2011-02-02
EP2270500A1 (en) 2011-01-05
EP2264186A1 (en) 2010-12-22
EP2270213A3 (en) 2011-06-29
EP2270211A3 (en) 2011-06-22
EP2270503A2 (en) 2011-01-05
EP2270216A3 (en) 2011-07-20
KR101075158B1 (ko) 2011-10-19
WO2004031413A3 (en) 2005-02-24
EP1743947A2 (en) 2007-01-17
EP2264457A1 (en) 2010-12-22
KR20050074468A (ko) 2005-07-18
EP2270212A2 (en) 2011-01-05
EP2270214A2 (en) 2011-01-05
EP2270220A2 (en) 2011-01-05
WO2004031413A2 (en) 2004-04-15
EP2270213A2 (en) 2011-01-05
WO2004031413A9 (en) 2005-08-04
EP2270214A3 (en) 2011-07-20
EP2270501A3 (en) 2011-01-19
EP2264190A1 (en) 2010-12-22
JP2006500949A (ja) 2006-01-12
EP2278028A1 (en) 2011-01-26
EP2270220A3 (en) 2011-09-28
EP2270219A2 (en) 2011-01-05
JP2012125247A (ja) 2012-07-05
EP2270210A2 (en) 2011-01-05
JP2009240313A (ja) 2009-10-22
EP2270219A3 (en) 2011-07-27
EP2270498A2 (en) 2011-01-05
JP4921522B2 (ja) 2012-04-25
EP2270223A2 (en) 2011-01-05
CA2500151A1 (en) 2004-04-15
EP2264187A1 (en) 2010-12-22
EP2270224A2 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
JP4921522B2 (ja) 非小細胞肺癌の診断のための方法
JP4679149B2 (ja) ヒト膵癌に関連する遺伝子およびポリペプチド
JP4594085B2 (ja) ヒト結腸癌に関連する遺伝子およびポリペプチド
JP5109131B2 (ja) 膀胱癌を診断する方法
CN1854313B (zh) 非小细胞肺癌的诊断方法
JP2006517783A (ja) ヒト骨髄性白血病に関連する遺伝子およびポリペプチド
CN101835894A (zh) Ebi3、dlx5、nptx1和cdkn3用作肺癌治疗和诊断的靶基因
JP2012511305A (ja) 癌の治療および診断の標的遺伝子としてのネクチン−４
US7521205B2 (en) Genes and polypeptides relating to prostate cancers
JP2009505633A (ja) Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法
JP2006500945A (ja) 結腸直腸癌の転移を治療または予防する方法
US8067153B2 (en) Genes and polypeptides relating to prostate cancers
JP2012501168A (ja) 腫瘍マーカー及び癌に対する治療標的としてのｔｂｃ１ｄ７
JP5109063B2 (ja) 乳癌に関連する遺伝子およびポリペプチド
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
JP2008505601A (ja) 前立腺癌に関連した遺伝子及びポリペプチド
JP2009505631A (ja) 癌関連遺伝子ｒａｓｇｅｆ１ａ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060908

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091208

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121218

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121218

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121218

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121218

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121218

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131218

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees